{"id":34812,"date":"2013-12-13T10:02:55","date_gmt":"2013-12-13T15:02:55","guid":{"rendered":"http:\/\/asweetlife.org\/?post_type=news&p=34812"},"modified":"2015-12-30T05:22:26","modified_gmt":"2015-12-30T10:22:26","slug":"fda-advisory-committee-votes-in-favor-of-newtype-2-diabetes-drug-dapagliflozin","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=34812","title":{"rendered":"FDA Advisory Committee Votes In Favor of NewType 2 Diabetes Drug, Dapagliflozin."},"content":{"rendered":"
\"\"<\/a>The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has decided (13-1) in favor of Bristol-Myers Squib and AstraZeneca’s type 2 diabetes drug, dapagliflozin. The committeee found that\u00a0the benefits of\u00a0dapagliflozin\u00a0use outweigh identified risks and support marketing of dapagliflozin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.\u00a0<\/div>\n
\n

The Advisory Committee also voted 10-4 that the data provided sufficient evidence that dapagliflozin, relative to comparators, has an acceptable cardiovascular risk profile.<\/p>\n

The FDA is not bound by the Advisory Committee\u2019s recommendation but takes its advice into consideration when reviewing the application for an investigational agent. The Prescription Drug User Fee Act (PDUFA) goal date for dapagliflozin is Jan. 11, 2014.<\/p>\n

Dapagliflozin is being reviewed by the FDA for use as monotherapy, and in combination with other antidiabetic agents, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body. Dapagliflozin, an investigational compound in the U.S., was the first SGLT2 inhibitor to be approved anywhere in the world. Dapagliflozin is currently approved under the trade name [Forxiga]\u2122 for the treatment of adults with type 2 diabetes, along with diet and exercise, in 38 countries, including the European Union and Australia.<\/p>\n

The EMDAC was provided with data from the extensive dapagliflozin global clinical development program included as part of the New Drug Application (NDA) and resubmission. In response to the FDA\u2019s Jan. 2012 complete response letter, the NDA resubmission included several new studies and additional long-term data (up to four years\u2019 duration) from previously submitted studies, resulting in an overall increase in patient-years exposure to dapagliflozin of more than 50 percent as compared to exposure in the original NDA. The resubmission included data from the dapagliflozin Phase II\/III clinical development program, which included more than 11,000 adult patients with diabetes (approximately 6,000 patients received dapagliflozin) in 24 clinical trials.<\/p>\n

Patient populations examined covered the range of diabetes progression, including drug-na\u00efve patients, patients inadequately controlled on oral therapies and patients on insulin-based regimens. The program also provided significant experience in elderly patients, patients with a history of cardiovascular (CV) disease, overweight and obese patients, patients with poorly controlled hypertension and patients with mild to moderate renal impairment. In accordance with FDA guidelines, the NDA resubmission also included data assessing the CV safety of dapagliflozin in adults with type 2 diabetes. Additionally, the DECLARE study is being conducted in patients with type 2 diabetes to determine the effect of dapagliflozin, when added to the patients\u2019 current anti-diabetes therapy, on the risk of CV events, such as CV death, myocardial infarction or ischemic stroke, compared with placebo. The randomized, double-blind, placebo-controlled study of more than 17,000 patients initiated enrollment in April 2013 and has an anticipated completion date of 2019.<\/p>\n

 <\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has decided (13-1) in favor of Bristol-Myers Squib and AstraZeneca’s type 2 diabetes drug, dapagliflozin. The committeee found that the benefits of dapagliflozin use outweigh identified risks and support marketing of dapagliflozin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. <\/p>\n","protected":false},"author":131,"featured_media":34813,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1442],"tags":[1332],"yoast_head":"\nFDA Advisory Committee Votes In Favor of NewType 2 Diabetes Drug, Dapagliflozin.<\/title>\n<meta name=\"description\" content=\"The FDA's Advisory Committee decided in favor of Bristol-Myers Squib and AstraZeneca's type 2 diabetes drug, dapagliflozin and found that the benefits of dapagliflozin outweigh identified risks\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=34812\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=34812\",\"url\":\"https:\/\/asweetlife.org\/?p=34812\",\"name\":\"FDA Advisory Committee Votes In Favor of NewType 2 Diabetes Drug, Dapagliflozin.\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=34812#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=34812#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/12\/Bristol-Myers-Squibb-AstraZeneca-Logo-home.jpg\",\"datePublished\":\"2013-12-13T15:02:55+00:00\",\"dateModified\":\"2015-12-30T10:22:26+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"The FDA's Advisory Committee decided in favor of Bristol-Myers Squib and AstraZeneca's type 2 diabetes drug, dapagliflozin and found that the benefits of dapagliflozin outweigh identified risks\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=34812#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=34812\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=34812#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/12\/Bristol-Myers-Squibb-AstraZeneca-Logo-home.jpg\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/12\/Bristol-Myers-Squibb-AstraZeneca-Logo-home.jpg\",\"width\":359,\"height\":228,\"caption\":\"Bristol-Myers Squibb - AstraZeneca Logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=34812#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Advisory Committee Votes In Favor of NewType 2 Diabetes Drug, Dapagliflozin.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Advisory Committee Votes In Favor of NewType 2 Diabetes Drug, Dapagliflozin.","description":"The FDA's Advisory Committee decided in favor of Bristol-Myers Squib and AstraZeneca's type 2 diabetes drug, dapagliflozin and found that the benefits of dapagliflozin outweigh identified risks","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=34812","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=34812","url":"https:\/\/asweetlife.org\/?p=34812","name":"FDA Advisory Committee Votes In Favor of NewType 2 Diabetes Drug, Dapagliflozin.","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=34812#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=34812#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/12\/Bristol-Myers-Squibb-AstraZeneca-Logo-home.jpg","datePublished":"2013-12-13T15:02:55+00:00","dateModified":"2015-12-30T10:22:26+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"The FDA's Advisory Committee decided in favor of Bristol-Myers Squib and AstraZeneca's type 2 diabetes drug, dapagliflozin and found that the benefits of dapagliflozin outweigh identified risks","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=34812#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=34812"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=34812#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/12\/Bristol-Myers-Squibb-AstraZeneca-Logo-home.jpg","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/12\/Bristol-Myers-Squibb-AstraZeneca-Logo-home.jpg","width":359,"height":228,"caption":"Bristol-Myers Squibb - AstraZeneca Logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=34812#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"FDA Advisory Committee Votes In Favor of NewType 2 Diabetes Drug, Dapagliflozin."}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/34812"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34812"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/34812\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/34813"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}